CN1406587A - 活性碳在制备治疗甲亢症的口服药物制剂中的应用 - Google Patents
活性碳在制备治疗甲亢症的口服药物制剂中的应用 Download PDFInfo
- Publication number
- CN1406587A CN1406587A CN01128840A CN01128840A CN1406587A CN 1406587 A CN1406587 A CN 1406587A CN 01128840 A CN01128840 A CN 01128840A CN 01128840 A CN01128840 A CN 01128840A CN 1406587 A CN1406587 A CN 1406587A
- Authority
- CN
- China
- Prior art keywords
- activated carbon
- hyperthyroidism
- patient
- disease
- oral drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01128840XA CN1281217C (zh) | 2001-09-13 | 2001-09-13 | 活性碳在制备治疗甲亢症的口服药物制剂中的应用 |
US10/489,505 US20040265299A1 (en) | 2001-09-13 | 2002-09-09 | Oral pharmaceutical formulation containing active carbon and use of the same |
DE60231997T DE60231997D1 (de) | 2001-09-13 | 2002-09-09 | Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung |
PCT/CN2002/000630 WO2003022292A1 (fr) | 2001-09-13 | 2002-09-09 | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation |
ES02754173T ES2322041T3 (es) | 2001-09-13 | 2002-09-09 | Formula farmaceutica oral con ingrediente activo de carbon y uso de la misma. |
JP2003526420A JP2005524604A (ja) | 2001-09-13 | 2002-09-09 | 活性炭を含有する経口製剤及びその用途 |
EP02754173A EP1437140B1 (en) | 2001-09-13 | 2002-09-09 | Oral pharmaceutical formulation containing active carbon and use of the same |
AT02754173T ATE428432T1 (de) | 2001-09-13 | 2002-09-09 | Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01128840XA CN1281217C (zh) | 2001-09-13 | 2001-09-13 | 活性碳在制备治疗甲亢症的口服药物制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1406587A true CN1406587A (zh) | 2003-04-02 |
CN1281217C CN1281217C (zh) | 2006-10-25 |
Family
ID=4668655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB01128840XA Expired - Fee Related CN1281217C (zh) | 2001-09-13 | 2001-09-13 | 活性碳在制备治疗甲亢症的口服药物制剂中的应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040265299A1 (zh) |
EP (1) | EP1437140B1 (zh) |
JP (1) | JP2005524604A (zh) |
CN (1) | CN1281217C (zh) |
AT (1) | ATE428432T1 (zh) |
DE (1) | DE60231997D1 (zh) |
ES (1) | ES2322041T3 (zh) |
WO (1) | WO2003022292A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021134482A1 (en) * | 2019-12-31 | 2021-07-08 | Fresenius Medical Care Deutschland Gmbh | Direct compressed activated carbon tablet formulation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112498A1 (en) * | 2003-06-20 | 2004-12-29 | Hill's Pet Nutrition, Inc. | Methods for hyperthyroidism in a cat and composition comprising limited iodine |
US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
CN101868242B (zh) * | 2007-11-23 | 2012-07-18 | 法莫隆登西斯股份公司 | 获得支气管舒张的方法和手段 |
JP5701971B2 (ja) * | 2011-03-04 | 2015-04-15 | 株式会社クレハ | 錠剤型の経口投与用組成物及びその製造方法 |
CN110151792A (zh) * | 2019-06-06 | 2019-08-23 | 合肥元佑健康管理有限公司 | 一种治疗甲亢的中药方及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3642986A (en) * | 1970-04-01 | 1972-02-15 | William Arthur Welch | Aspirin-charcoal compositions |
US5554370A (en) * | 1994-05-27 | 1996-09-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for the treatment of inflammatory bowel diseases |
-
2001
- 2001-09-13 CN CNB01128840XA patent/CN1281217C/zh not_active Expired - Fee Related
-
2002
- 2002-09-09 ES ES02754173T patent/ES2322041T3/es not_active Expired - Lifetime
- 2002-09-09 EP EP02754173A patent/EP1437140B1/en not_active Expired - Lifetime
- 2002-09-09 DE DE60231997T patent/DE60231997D1/de not_active Expired - Lifetime
- 2002-09-09 JP JP2003526420A patent/JP2005524604A/ja active Pending
- 2002-09-09 US US10/489,505 patent/US20040265299A1/en not_active Abandoned
- 2002-09-09 AT AT02754173T patent/ATE428432T1/de not_active IP Right Cessation
- 2002-09-09 WO PCT/CN2002/000630 patent/WO2003022292A1/zh active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021134482A1 (en) * | 2019-12-31 | 2021-07-08 | Fresenius Medical Care Deutschland Gmbh | Direct compressed activated carbon tablet formulation |
Also Published As
Publication number | Publication date |
---|---|
WO2003022292A1 (fr) | 2003-03-20 |
EP1437140A1 (en) | 2004-07-14 |
EP1437140A4 (en) | 2005-06-22 |
JP2005524604A (ja) | 2005-08-18 |
CN1281217C (zh) | 2006-10-25 |
EP1437140B1 (en) | 2009-04-15 |
DE60231997D1 (de) | 2009-05-28 |
ES2322041T3 (es) | 2009-06-16 |
US20040265299A1 (en) | 2004-12-30 |
ATE428432T1 (de) | 2009-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4750358B2 (ja) | 真皮下軟組織の痛みの治療のためのストロンチウム化合物 | |
Strauss et al. | Effect of cyclic progestin-estrogen therapy on sebum and acne in women | |
CN101292969B (zh) | 丁酸(酪酸)在制备治疗肛肠疾病药物中的应用 | |
JPH10500678A (ja) | 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用 | |
CN1281217C (zh) | 活性碳在制备治疗甲亢症的口服药物制剂中的应用 | |
Yassa et al. | Hair loss in the course of lithium treatment: a report of two cases | |
Amure | Clinical study of Duogastrone in the treatment of duodenal ulcers | |
BERGFELT et al. | Preoperative treatment of thyrotoxicosis with antithyroid drugs and thyroxine | |
Bideau et al. | Acute hypermagnesemia and respiratory arrest following infusion of MgSO4 for tocolysis | |
Ivey et al. | Effect of carbenoxolone on the gastric mucosal barrier in man after administration of taurocholic acid | |
Eriksen et al. | Oral retinoic acid as therapy for congenital ichthyosiform erythroderma | |
CN101474397A (zh) | 治疗甲亢的注射液 | |
Irnell | Metastatic calcification of soft tissue on overdosage of vitamin D | |
Rose et al. | Effect of dihydrotachysterol in treatment of parathyroid deficiency | |
Russell et al. | Mithramycin therapy in Paget's disease | |
EP0530220A1 (en) | PHARMACEUTICAL COMPOSITION. | |
Tewari et al. | Papillary thyroid carcinoma manifesting as thyroid storm of pregnancy: case report | |
Thompson | Case Number 16 Amitriptyline Overdose | |
Ganesan et al. | A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia | |
Oster et al. | Hyporeninemic hypoaldosteronism after chronic sodium bicarbonate abuse | |
HARELL-STEINBERG et al. | Observations on hypoparathyroidism. I. Exfoliative dermatitis as the presenting sign of hypoparathyroidism: a case report | |
Browne | The case for intravenous magnesium treatment of arterial disease in general practice: review of 34 years of experience | |
Margulies et al. | Terbutaline-induced hypotension in a pregnant asthmatic patient | |
Ortega-Carnicer et al. | Long QT interval in severe hypercalcaemia | |
RU2146129C1 (ru) | Лекарственное средство |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN GUANGSHENG INVESTMENT MANAGEMENT CO., LTD. Free format text: FORMER OWNER: CHEN DECAI Effective date: 20100625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 DEPARTMENT OF ENDOCRINOLOGY EST CHINA HOSPITAL OF SICHUAN UNIVERSITY O.37 WAINAN GUOXUE LANE, CHENGDU CITY, SICHUAN PROVINCE TO: 610017 NO.99-9, XIQU STREET, CHENGDU HIGH + NEW TECHNOLOGY INDUSTRIAL DEVELOPMENT ZONE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100625 Address after: 610017, 99 West Avenue, Chengdu hi tech Zone, attached No. 9 Patentee after: Sichuan wins Cci Capital Ltd Address before: 610041 Department of Endocrinology, West China Hospital,, Chengdu 37, Sichuan, China Patentee before: Chen Decai |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061025 Termination date: 20140913 |
|
EXPY | Termination of patent right or utility model |